Commentary

Video

Supplements and Featured Publications

Examining Recent Updates in ROS1+ NSCLC
Volume1
Issue 1

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

Author(s):

Fact checked by:

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Tony S. K. Mok, BMSc, MD, FASCO, Li Shu Fan Medical Foundation Endowed Professor, chairman, Department of Clinical Oncology, Chinese University of Hong Kong, discusses efficacy findings from a pooled analysis of the phase 2 TRUST-I (NCT04395677) and TRUSTII (NCT04919811) trials investigating taletrectinib (AB-106) in advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC).

This pooled analysis showed the efficacy of the second-generation ROS1 TKI taletrectinib in patients with ROS1-positive NSCLC. In the TKI-naive cohort, the confirmed overall response rate (cORR) with taletrectinib was 88.8% (95% CI, 82.8%-93.2%). In total, 20% of patients in this cohort had received prior chemotherapy. Additionally, the median progression-free survival (PFS) was 45.6 months (95% CI, 29.0-not reached [NR]), and the median duration of response was 44.2 months (95% CI, 30.4-NR), highlighting the long-term benefit of this agent, Mok says.

Among patients in the TKI-pretreated cohort, the cORR was 55.8% (95% CI, 46.1%-65.1%). In total, 37% of the patients in this cohort had received prior chemotherapy. The study also provided notable insights into outcomes among patients harboring the G2320R resistance mutation, Mok emphasizes. Of the 13 TKI-pretreated patients who expressed this mutation, 8 responded to treatment with taletrectinib. This translated to a cORR of 61.5% (95% CI, 31.6%-86.1%). Furthermore, the median PFS was 9.7 months (95% CI, 7.4-12.0), and the median DOR was 16.6 months (95% CI, 10.6-27.3) in all TKI-pretreated patients.

These efficacy findings underscore the efficacy of taletrectinib within the broader context of ROS1-targeted therapy, Mok explains. Although the TKI crizotinib (Xalkori) generated notable PFS outcomes in earlier studies of patients with ROS1-positive NSCLC, second- and third-generation TKIs, such as entrectinib (Rozlytrek) and lorlatinib (Lorbrena), have also demonstrated enhanced efficacy, he says. No head-to-head comparisons of these agents have been conducted; however, newer second-generation TKIs, including taletrectinib, likely offer superior PFS, ORR, and central nervous system efficacy, he reports.

Notably, in the pooled analysis of TRUST-I and TRUST-II, taletrectinib led to an intracranial ORR of 76.5% (95% CI, 50.1%-93.2%) in TKI-naive patients. These data reinforce the agent’s potential utility as a first-line therapy for patients with ROS1-positive NSCLC, particularly those with brain metastases, Mok concludes.

The most common treatment-related adverse effects (TEAEs) were elevated liver enzyme levels and gastrointestinal issues. Neurologic TEAEs included dizziness in 21.1% of patients and dysgeusia in 14.5% of patients; most neurologic TEAEs were grade 1.

Related Videos
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD